Merck KGaA said it has taken back Japan marketing rights for its best-selling Erbitux (cetuximab) cancer drug, ending its shared arrangement with Bristol-Myers Squibb effective May 1.
Glenmark's chairman and managing director says his company is looking for a series of partners around the world to market 7 molecules for various treatments it has in development, all but one in clinical trials.
Johnson & Johnson's Janssen unit is teaming up with nonprofit JDRF to develop new diagnostic approaches for Type 1 diabetes, aiming to identify the disease earlier and curb its progression.
Advaxis, on a partnering spree after joining with Merck and AstraZeneca to test its cancer vaccine candidates in immunotherapy combos, has teamed up with Incyte to trial one of its prospects in cervical cancer.
Advaxis has signed a deal to study its in-development immuno-oncology candidate in tandem with a complementary cancer drug from Incyte, the latest combo trial in a field rife with collaboration.
Patient monitoring player Welch Allyn has partnered with software company Spok to connect its vital signs monitors to the mobile devices of healthcare practitioners. The idea of a systemwide connection approach is to better prioritize and not overwhelm staff with device-related alarms.
Sanofi subsidiary Genzyme is tying up with gene therapy upstart Voyager Therapeutics, gambling $100 million upfront on the hot field and promising up to $745 million in milestones for their partnership on a full slate of development programs.
Merck and Novo Nordisk are the latest pharma recruits for the GPCR Consortium, a global nonprofit working to shed light on an underexplored corner of biology and share its discoveries with the public.
CareFusion has made a pair of marketing deals, one to sell a line of ventilation equipment from Breas Medical and the other to distribute a sleep apnea device from Apnea Sciences. The financial terms of both deals remain undisclosed.
South Korea's Celltrion will start sales of Remsima, its biosimilar of Johnson & Johnson's Remicade (infliximab) in a dozen European countries in February, according to Joon Seok Kim of Celltrion Public Relations on Tuesday.